Immatics N.V.
Latest round
- Series E
Last raised
- Jun 2017
Total raised
- $237M
Investors
- 17
About Immatics N.V.
V. specializes in creating novel cancer immunotherapies, focusing on T Cell Receptor Therapy (TCR-T) and TCR Bispecifics. Founded in 2000 in Tuebingen, Germany, the company underwent a merger with Arya Sciences Acquisition Corp. in July 2020, significantly enhancing its operational scope.00 mn.Immatics specializes in the development of innovative cancer immunotherapies, utilizing its proprietary technologies to create targeted treatments aimed at engaging T cells against tumor cells. The company's primary product offerings include TCR-T (T Cell Receptor Therapy) and TCR Bispecifics, designed to recognize and attack cancerous cells. These therapies leverage Immatics' XPRESIDENT® technology to identify true tumor targets, facilitating a precise immune response for patients suffering from various cancers, particularly those expressing the PRAME target found in over 50 malignancies.86 mn. The company generates revenue through strategic partnerships and collaborations in the biopharmaceutical sector, focusing on the development of its advanced immunotherapies.V. plans to expand its product offerings, focusing on the development of additional immunotherapy solutions to address unmet needs in oncology. The company targets expansion into North American and European markets, with specific timelines yet to be defined. As part of its growth strategy, Immatics aims to leverage its technologies to enhance its therapeutic pipeline and establish stronger partnerships in the pharmaceutical industry.
Who invested in Immatics N.V.
17 investors across 7 rounds
See all investors in Immatics N.V.
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series E
Jun 28, 2017
Amount
$58M
Investors
Series D
Jul 25, 2014
Amount
$30M
Investors
Series D
Oct 7, 2013
Amount
$16M
Investors
Series C
Sep 7, 2010
Amount
$69M
Investors
Series B
Feb 19, 2007
Amount
$54M
Investors
Series A
Apr 28, 2004
Amount
$0.6M
Investors
Series A
Feb 11, 2004
Amount
$9.8M
Investors
Questions about Immatics N.V.
Who invested in Immatics N.V.?
Immatics N.V. has 17 investors on record across 7 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Immatics N.V. raised?
Immatics N.V. has raised 7 venture rounds. Sign up free to see how much each round raised and the total.
When did Immatics N.V. last raise money?
Immatics N.V.'s most recent round on record is a Series E, in Jun 2017.
What does Immatics N.V. do?
Immatics N.V. is a biotechnology company.
Where is Immatics N.V. headquartered?
Immatics N.V. is headquartered in Tuebingen, Germany.
Which VCs invest in companies like Immatics N.V.?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Generation Investment Management back biotechnology companies at Immatics N.V.'s stage. Their profiles are linked below.
VCs backing biotechnology startups at Series E
Raising like Immatics N.V.? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.